Arbutus Biopharma Corporation (ABUS)

3.1700 +0.0600 (+1.93%) At close: 4:00PM EDT

Arbutus Biopharma Corporation

701 Veterans Circle
Warminster, PA 18974
United States
267 469 0914
http://www.arbutusbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 76

Key executives

Name	Title	Pay	Exercised	Year born
Mr. William H. Collier	Pres, CEO & Director	542.14k	N/A	1960
Mr. David C. Hastings	CFO & Chief Accounting Officer	551.14k	N/A	1961
Dr. Michael J. Sofia	Chief Scientific Officer	567.24k	N/A	1958
Pam Murphy	Investor Relations Consultant	N/A	N/A	N/A
Dr. Elizabeth Howard	Exec. VP, Gen. Counsel & Chief Compliance Officer	N/A	N/A	1954
Dr. Gaston Picchio Ph.D.	Chief Devel. Officer	N/A	N/A	1963
Mr. Michael J. McElhaugh	Chief Bus. Officer	N/A	N/A	1974
Mr. R. Hector Mackay-Dunn B.A., L.L.B., Q.C., J.D., Q.C	Sec.	N/A	N/A	1951

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Corporate governance

Arbutus Biopharma Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.